MORPHINE SULFATE INJECTION USP SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

MORPHINE SULFATE

Disponible desde:

ICU MEDICAL CANADA INC

Código ATC:

N02AA01

Designación común internacional (DCI):

MORPHINE

Dosis:

5MG

formulario farmacéutico:

SOLUTION

Composición:

MORPHINE SULFATE 5MG

Vía de administración:

INTRAVENOUS

Unidades en paquete:

30ML

tipo de receta:

Narcotic (CDSA I)

Área terapéutica:

OPIATE AGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0104545003; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2019-10-14

Ficha técnica

_ _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 1 of 32 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MORPHINE SULFATE INJECTION USP
Sterile Solution
1 mg/mL, 5 mg/mL
Narcotic Analgesic
ICU Medical Canada Inc.
2600, Alfred-Nobel boul., suite 100
Saint-Laurent, QC
H4S 0A9
Date of Revision:
April 4, 2018
Submission Control No: 211418
_ _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 2 of 32 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
.......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
................................................................................24
PHARMACEUTICAL INFORMATION
..................................................................